ArticleNature2024
The CRISPR effector Cam1 mediates membrane depolarization for phage defence.
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- How bacterial immune systems sense phage infection.Nature reviews. Microbiology · 2026Review
- Rapid and quantitative measurement of bacteriophage infectivity via fully automated droplet digital PCR.Nature communications · 2026Article
- Prokaryotic Schlafen proteins cleave tRNAs during type III CRISPR immunity.Nature communications · 2026Article
- Structural mechanism of SAM-AMP and SAM-AMPNature communications · 2026Article
- The CRISPR ring nuclease Csx15 oligomerises on cyclic nucleotide binding to regulate antiviral defence.The Biochemical journal · 2026Article
- Bacterial 2',3'-cGAMP activates a SAVED effector to form membrane-disrupting filaments and restrict phage replication.Cell host & microbe · 2026Article
- Structural plasticity enables broad cAn binding and dual activation of CRISPR-associated ribonuclease Cdn1.Nucleic acids research · 2026Article
- CARF-HAD phosphatase effectors provide immunity during the type III-A CRISPR-Cas response.Nucleic acids research · 2025Article
- Cap1 forms a cyclic tetra-adenylate-induced membrane pore during the type III-A CRISPR-Cas immune response.bioRxiv : the preprint server for biology · 2025Article
- A viral SAVED protein with ring nuclease activity degrades the CRISPR second messenger cA4.The Biochemical journal · 2025Article
- A prophage intercepts pathogenic activity of infecting phage for defense.Cell host & microbe · 2025Article
- Diversity and abundance of ring nucleases in type III CRISPR-Cas loci.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- SAM-AMP lyases in type III CRISPR defence.Nucleic acids research · 2025Article
- Cat1 forms filament networks to degrade NADScience (New York, N.Y.) · 2025Article
- Nucleic acid recognition during prokaryotic immunity.Molecular cell · 2025Review
- Mechanistic determinants and dynamics of cA6 synthesis in type III CRISPR-Cas effector complexes.Nucleic acids research · 2025Article
- The CRISPR-associated adenosine deaminase Cad1 converts ATP to ITP to provide antiviral immunity.Cell · 2024Article
- Cas10 relieves host growth arrest to facilitate spacer retention during type III-A CRISPR-Cas immunity.Cell host & microbe · 2024Article
- Bioinformatic analysis of type III CRISPR systems reveals key properties and new effector families.Nucleic acids research · 2024Article
- CRISPR antiphage defence mediated by the cyclic nucleotide-binding membrane protein Csx23.Nucleic acids research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Prokaryotic type III CRISPR-Cas systems provide immunity against viruses and plasmids using CRISPR-associated Rossman fold (CARF) protein effectors
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.